Summary & Overview
CPT 90683: RSV mRNA Vaccine, Intramuscular
CPT code 90683 denotes an intramuscular mRNA vaccine formulated with lipid nanoparticles to protect against respiratory syncytial virus (RSV). As an approved preventive immunization product, this code is important nationally for vaccination programs, immunization billing, and public health efforts to reduce RSV-related morbidity among eligible populations. The code captures the vaccine product rather than the administration service alone and is used in outpatient and ambulatory immunization settings.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for RSV mRNA vaccination, typical sites of service, common billing modifiers associated with vaccine services, and where available, payer coverage patterns and policy considerations. The content summarizes benchmarks and reimbursement context where available, highlights relevant policy updates affecting vaccine coding and coverage, and provides practical billing context for coders and revenue teams.
This national-level summary is intended to inform clinical billing staff, revenue cycle managers, and policy analysts about the role of CPT code 90683 in current immunization practice and payer interactions. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 90683 represents an mRNA vaccine administered intramuscularly for protection against respiratory syncytial virus (RSV). The product is formulated with lipid nanoparticles to deliver mRNA encoding RSV antigens.
Service Type: Vaccine administration (intramuscular)
Typical Site of Service: Outpatient clinic, primary care office, pharmacy immunization setting, or other ambulatory care sites
Clinical & Coding Specifications
Clinical Context
A 68-year-old adult with chronic obstructive pulmonary disease (COPD) and congestive heart failure presents to an outpatient primary care clinic during RSV season requesting immunization. The clinician verifies vaccination history, reviews contraindications (severe allergic reaction to prior dose or vaccine component), assesses current illness and acute febrile conditions, obtains informed consent, and documents lot number and manufacturer. The vaccine is administered intramuscularly in the deltoid by a licensed nurse. The patient is observed for 15–30 minutes for immediate adverse reactions. Documentation includes vaccine product, dose, route, anatomical site, date, lot number, expiration, and the administering provider’s name and taxonomy. Billing uses 90683 for the mRNA lipid nanoparticle respiratory syncytial virus vaccine, with appropriate CPT-level encounter codes for the visit and any vaccine administration modifiers if required by the payer. Typical sites of service are outpatient clinic, physician office, federally qualified health center, and pharmacy immunization clinic. The service type is a preventive immunization/vaccine administration given intramuscularly for RSV prophylaxis in adults at increased risk of severe disease.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier standard — reporter-defined; rarely used in claims | Use only if a payer specifically requires on submissions for a neutral modifier field. |